How Investors May Respond To Edwards Lifesciences (EW) Expanded TAVR Access And Transcatheter Valve Ambitions
Edwards Lifesciences Corp EW
$88.08
▲ +1.44%
(+$1.25)
Index member:
S&P 500
⬆️ Above Yest. High
Open
$85.70
Prev Close
$86.83
Day Range
$85.70 – $88.19
52W Range
$72.30 – $96.29
Market Cap
$49.41B
P/E (TTM)
49.72
Beta
0.85
EPS (TTM)
$1.73
📋 Company Profile
| Industry | Health Care |
| Country | US |
| Exchange | NEW YORK STOCK EXCHANGE, INC. |
| Currency | USD |
| IPO Date | 2000-03-27 |
| Shares Out. | 575,800,000 |
| Website | edwards.com ↗ |
| Phone | 13026587581 |
| Employees | 16,000 |
| Revenue | $1.74B |
| Gross Profit | $1.35B |
| Net Income | $241.4M |
| Free Cash Flow | $1.43B |
| Total Assets | $13.87B |
| Total Liabilities | $3.14B |
| Equity | $10.72B |
About Edwards Lifesciences Corp
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
Edwards Lifesciences Corp is a publicly traded company under the ticker symbol EW on the NEW YORK STOCK EXCHANGE, INC., operating in the Health Care industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
40 analysts (2026-09-01)
📰 Latest News for EW
Edwards Lifesciences (EW) Stock Looks Reasonable After Medicare TAVR Expansion
Interventional Cardiology Devices Market by Type, End User - Global Forecast to 2031
Edwards Lifesciences Sees TAVR Expansion, $2B TMTT Opportunity Ahead
Explore the top gainers and losers within the S&P500 index in today's session.
What's going on in today's session: S&P500 movers
Edwards Lifesciences Corporation (EW) Presents at Deutsche Bank 2026 Healthcare Summit Transcript

